Biotech Values

[Biowatch]

GILD says TEVA files ANDA for generic Atripla

http://finance.yahoo.com/news/Gilead-Sciences-Announces-bw-14863194.html

>>...Teva alleges that two of the patents associated with emtricitabine – U.S. Patent Numbers 6,642,245 and 6,703,396 – owned by Emory University and licensed exclusively to Gilead Sciences... will not be infringed by Teva...

Gilead... has 45 days from the date of receipt to commence a patent infringement lawsuit against Teva. Such a lawsuit would restrict the FDA from approving Teva’s ANDA for up to 30 months or until a district court decision that is adverse to Gilead, whichever occurs first...

...In November 2008, Teva challenged the validity of these same two emtricitabine patents... with an ANDA filing for Truvada®... [GILD filed a lawsuit which] is ongoing.<<